Mass spectrometry for the detection of minimal residual disease (MRD) in myeloma

Bookmark and Share
Published: 25 Sep 2020
Views: 2216
Dr Noemí Puig - Hospital Universitario de Salamanca, Salamanca, Spain

Dr Noemi Puig speaks to ecancer online at the MyKE20 meeting about the new techniques to detect minimal residual disease (MRD) in the bone marrow.

She outlines some of the barriers which face detecting this MRD, and why mass spectrometry was chosen to be studied for its effectiveness.

Dr Puig outlines this trial design, and how successful the mass spectrometry was in detecting MRD.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.